TG Therapeutics, Inc. (TGTX)
59.82
+1.84
(+3.18%)
USD |
NASDAQ |
Nov 06, 16:00
59.85
+0.02
(+0.04%)
After-Hours: 20:00
TG Therapeutics Research and Development Expense (Annual) : 160.22M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 160.22M |
| December 31, 2024 | 94.29M |
| December 31, 2023 | 76.19M |
| December 31, 2022 | 125.35M |
| December 31, 2021 | 222.58M |
| December 31, 2020 | 165.90M |
| December 31, 2019 | 154.18M |
| December 31, 2018 | 159.39M |
| December 31, 2017 | 102.53M |
| December 31, 2016 | 69.23M |
| December 31, 2015 | 47.71M |
| December 31, 2014 | 40.09M |
| December 31, 2013 | 13.66M |
| December 31, 2012 | 21.03M |
| Date | Value |
|---|---|
| December 31, 2011 | 0.3273M |
| December 31, 2010 | 0.4958M |
| December 31, 2009 | 0.0404M |
| December 31, 2008 | 1.803M |
| December 31, 2007 | 8.536M |
| December 31, 2006 | 6.173M |
| December 31, 2005 | 5.178M |
| December 31, 2004 | 4.153M |
| December 31, 2003 | 1.724M |
| December 31, 2002 | 0.5398M |
| December 31, 2001 | 0.8867M |
| December 31, 2000 | 1.130M |
| December 31, 1999 | 1.091M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Amneal Pharmaceuticals, Inc. | 186.18M |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| SELLAS Life Sciences Group, Inc. | 16.02M |
| Travere Therapeutics, Inc. | 206.01M |